Selective Androgen Receptor Modulators (SARMs) are a class of compounds that selectively activate the androgen receptor (AR) in a tissue-specific manner. By doing so, they offer the potential for therapeutic benefits with reduced side effects compared to traditional androgenic compounds [1]. SARMs have gained attention in recent years due to their ability to elicit beneficial anabolic effects while avoiding many of the unwanted side effects associated with steroidal agents [2].

SARMs have been proposed as potential treatments for various diseases, including muscle wasting, breast cancer, osteoporosis, and hypogonadism [1,3,4]. In addition, SARMs have been shown to stimulate AR-mediated gene expression and promote anabolic effects in muscle and bone [9].

Read our SARMs beginners guide and check out the published SARMs articles and research below.


  1. Narayanan, R., Coss, C., Dalton, J. (2018). Development Of Selective Androgen Receptor Modulators (Sarms). Molecular and Cellular Endocrinology, (465), 134-142.
  2. Dodson, S., Baracos, V., Jatoi, A., Evans, W., Cella, D., Dalton, J., … & Steiner, M. (2011). Muscle Wasting In Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annu. Rev. Med., 1(62), 265-279.
  3. Solomon, Z., Mirabal, J., Mazur, D., Kohn, T., Lipshultz, L., Pastuszak, A. (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews, 1(7), 84-94.
  4. Bhasin, S., Jasuja, R. (2009). Selective Androgen Receptor Modulators As Function Promoting Therapies. Current Opinion in Clinical Nutrition and Metabolic Care, 3(12), 232-240.
  5. Dalton, J., Barnette, K., Bohl, C., Hancock, M., Rodriguez, D., Dodson, S., … & Steiner, M. (2011). The Selective Androgen Receptor Modulator Gtx‐024 (Enobosarm) Improves Lean Body Mass and Physical Function In Healthy Elderly Men And Postmenopausal Women: Results Of A Double‐blind, Placebo‐controlled Phase II Trial. J cachexia sarcopenia muscle, 3(2), 153-161.
  6. Mohler, M., Bohl, C., Jones, A., Coss, C., Narayanan, R., He, Y., … & Miller, D. (2009). Nonsteroidal Selective Androgen Receptor Modulators (Sarms): Dissociating the Anabolic And Androgenic Activities Of The Androgen Receptor For Therapeutic Benefit. J. Med. Chem., 12(52), 3597-3617.
  7. Panneerselvam, P., Singh, L., Selvarajan, V., Chng, W., Ng, S., Tan, N., … & Ding, J. (2012). T-cell Death Following Immune Activation Is Mediated By Mitochondria-localized Sarm. Cell Death Differ, 3(20), 478-489.
  8. Peng, J., Yuan, Q., Lin, B., Panneerselvam, P., Wang, X., Luan, X., … & Ding, J. (2010). Sarm Inhibits Both Trif- and Myd88-mediated Ap-1 Activation. Eur. J. Immunol., 6(40), 1738-1747.
  9. Yin, D., Gao, W., Kearbey, J., Xu, H., Chung, K., He, Y., … & Dalton, J. (2002). Pharmacodynamics Of Selective Androgen Receptor Modulators. J Pharmacol Exp Ther, 3(304), 1334-1340.